COMPASS Pathways (NASDAQ:CMPS) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

COMPASS Pathways (NASDAQ:CMPS) released its earnings results on Thursday. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.03), Zacks reports. During the same quarter in the prior year, the company earned ($0.62) EPS.

COMPASS Pathways Stock Performance

NASDAQ:CMPS traded up $0.16 during mid-day trading on Friday, reaching $7.04. The company’s stock had a trading volume of 598,895 shares, compared to its average volume of 423,448. The company has a current ratio of 15.23, a quick ratio of 15.23 and a debt-to-equity ratio of 0.12. The stock has a market cap of $481.40 million, a P/E ratio of -2.97 and a beta of 2.27. The firm’s fifty day moving average price is $6.89 and its two-hundred day moving average price is $8.58. COMPASS Pathways has a 12-month low of $5.01 and a 12-month high of $12.75.

Analyst Upgrades and Downgrades

CMPS has been the topic of a number of recent research reports. Canaccord Genuity Group reduced their price objective on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday. Royal Bank of Canada assumed coverage on COMPASS Pathways in a report on Tuesday, July 23rd. They set an “outperform” rating and a $23.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a research note on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a report on Friday, June 21st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $43.00.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.